Acurx Pharmaceuticals (ACXP) investor relations material

Company overview and business model

• Late-stage biopharmaceutical company developing small molecule antibiotics targeting Gram-positive bacteria, including priority pathogens such as C. difficile, MRSA, VRE, drug-resistant S. pneumoniae, and anthrax.

• Focused on addressing antimicrobial resistance with novel candidates that inhibit DNA polymerase IIIC, leading to bacterial cell death.

• Pipeline includes candidates for both initial and recurrent C. difficile infection, with new clinical trials planned for recurrent cases.

• Incorporated in Delaware, converted from LLC to corporation in 2021, principal offices in Staten Island, NY.

Financial performance and metrics

• As of December 31, 2025, net tangible book value was $5.3 million ($2.24 per share).

• After the offering, as adjusted net tangible book value would be $8.0 million ($2.20 per share), with an immediate decrease of $0.04 per share for existing stockholders.

• April 2026 registered direct offering raised $2.5 million gross, with additional private placement warrants issued.

• Common stock last traded at $2.16 per share on May 1, 2026.

Use of proceeds and capital allocation

• May receive up to $4.7 million in gross proceeds from sales to Lincoln Park under the Purchase Agreement, in addition to $7.3 million previously received.

• Proceeds intended for working capital and general corporate purposes, including R&D and administrative expenses.

• Management has broad discretion over use of proceeds; amounts and timing of expenditures may vary.